124 related articles for article (PubMed ID: 17108057)
1. Triethylenetetramine and metabolites: levels in relation to copper and zinc excretion in urine of healthy volunteers and type 2 diabetic patients.
Lu J; Chan YK; Gamble GD; Poppitt SD; Othman AA; Cooper GJ
Drug Metab Dispos; 2007 Feb; 35(2):221-7. PubMed ID: 17108057
[TBL] [Abstract][Full Text] [Related]
2. Determination of triethylenetetramine (TETA) and its metabolites in human plasma and urine by liquid chromatography-mass spectrometry (LC-MS).
Lu J; Chan YK; Poppitt SD; Cooper GJ
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Nov; 859(1):62-8. PubMed ID: 17901001
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, pharmacodynamics, and metabolism of triethylenetetramine in healthy human participants: an open-label trial.
Lu J; Poppitt SD; Othman AA; Sunderland T; Ruggiero K; Willett MS; Diamond LE; Garcia WD; Roesch BG; Cooper GJ
J Clin Pharmacol; 2010 Jun; 50(6):647-58. PubMed ID: 20145262
[TBL] [Abstract][Full Text] [Related]
4. Complex formation equilibria of Cu(II) and Zn(II) with triethylenetetramine and its mono- and di-acetyl metabolites.
Nurchi VM; Crisponi G; Crespo-Alonso M; Lachowicz JI; Szewczuk Z; Cooper GJ
Dalton Trans; 2013 May; 42(17):6161-70. PubMed ID: 23202417
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and pharmacodynamic modeling of a copper-selective chelator (TETA) in healthy adults.
Cho HY; Blum RA; Sunderland T; Cooper GJ; Jusko WJ
J Clin Pharmacol; 2009 Aug; 49(8):916-28. PubMed ID: 19602718
[TBL] [Abstract][Full Text] [Related]
6. Molecular changes evoked by triethylenetetramine treatment in the extracellular matrix of the heart and aorta in diabetic rats.
Gong D; Lu J; Chen X; Choong SY; Zhang S; Chan YK; Glyn-Jones S; Gamble GD; Phillips AR; Cooper GJ
Mol Pharmacol; 2006 Dec; 70(6):2045-51. PubMed ID: 16973718
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of a rapid HPLC method for the simultaneous determination of triethylenetetramine and its two main metabolites in human serum.
Othman A; Lu J; Sunderland T; Cooper GJ
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Dec; 860(1):42-8. PubMed ID: 17980682
[TBL] [Abstract][Full Text] [Related]
8. Quantitative proteomic profiling identifies new renal targets of copper(II)-selective chelation in the reversal of diabetic nephropathy in rats.
Gong D; Chen X; Middleditch M; Huang L; Vazhoor Amarsingh G; Reddy S; Lu J; Zhang S; Ruggiero K; Phillips AR; Cooper GJ
Proteomics; 2009 Sep; 9(18):4309-20. PubMed ID: 19634143
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic potential of copper chelation with triethylenetetramine in managing diabetes mellitus and Alzheimer's disease.
Cooper GJ
Drugs; 2011 Jul; 71(10):1281-320. PubMed ID: 21770477
[TBL] [Abstract][Full Text] [Related]
10. Copper(II)-selective chelation improves function and antioxidant defences in cardiovascular tissues of rats as a model of diabetes: comparisons between triethylenetetramine and three less copper-selective transition-metal-targeted treatments.
Lu J; Gong D; Choong SY; Xu H; Chan YK; Chen X; Fitzpatrick S; Glyn-Jones S; Zhang S; Nakamura T; Ruggiero K; Obolonkin V; Poppitt SD; Phillips AR; Cooper GJ
Diabetologia; 2010 Jun; 53(6):1217-26. PubMed ID: 20221822
[TBL] [Abstract][Full Text] [Related]
11. Copper, chromium, manganese, iron, nickel, and zinc levels in biological samples of diabetes mellitus patients.
Kazi TG; Afridi HI; Kazi N; Jamali MK; Arain MB; Jalbani N; Kandhro GA
Biol Trace Elem Res; 2008 Apr; 122(1):1-18. PubMed ID: 18193174
[TBL] [Abstract][Full Text] [Related]
12. Triethylenetetramine pharmacology and its clinical applications.
Lu J
Mol Cancer Ther; 2010 Sep; 9(9):2458-67. PubMed ID: 20660601
[TBL] [Abstract][Full Text] [Related]
13. [Urinary copper excretion from rats following administration of aliphatic and alicyclic polyamines (author's transl)].
Harders H; Armah B; Cohnen E; Führ J; Heinz N; Schröder HF
Arzneimittelforschung; 1980; 30(2):254-8. PubMed ID: 7378100
[TBL] [Abstract][Full Text] [Related]
14. Reversal of diabetes-evoked changes in mitochondrial protein expression of cardiac left ventricle by treatment with a copper(II)-selective chelator.
Jüllig M; Chen X; Hickey AJ; Crossman DJ; Xu A; Wang Y; Greenwood DR; Choong YS; Schönberger SJ; Middleditch MJ; Phillips AR; Cooper GJ
Proteomics Clin Appl; 2007 Apr; 1(4):387-99. PubMed ID: 21136691
[TBL] [Abstract][Full Text] [Related]
15. Fate of orally administered triethylenetetramine dihydrochloride: a therapeutic drug for Wilson's disease.
Kodama H; Meguro Y; Tsunakawa A; Nakazato Y; Abe T; Murakita H
Tohoku J Exp Med; 1993 Jan; 169(1):59-66. PubMed ID: 8211970
[TBL] [Abstract][Full Text] [Related]
16. Selective divalent copper chelation for the treatment of diabetes mellitus.
Cooper GJ
Curr Med Chem; 2012; 19(17):2828-60. PubMed ID: 22455587
[TBL] [Abstract][Full Text] [Related]
17. Contribution to the data on copper concentration in blood and urine in patients with Wilson's disease and in normal subjects.
Lech T; Sadlik JK
Biol Trace Elem Res; 2007 Jul; 118(1):16-20. PubMed ID: 17848726
[TBL] [Abstract][Full Text] [Related]
18. Twenty-nine year study on circadian distribution of urinary zinc levels of same male subjects.
Kanabrocki EL; Ryan MD; Marks G; Friedman NC; Kaplan E; Nemchausky BA
Clin Ter; 2007; 158(5):403-8. PubMed ID: 18062346
[TBL] [Abstract][Full Text] [Related]
19. Tetramine cupruretic agents: a comparison in dogs.
Allen KG; Twedt DC; Hunsaker HA
Am J Vet Res; 1987 Jan; 48(1):28-30. PubMed ID: 3826839
[TBL] [Abstract][Full Text] [Related]
20. Circadian characteristics of serum calcium, magnesium and eight trace elements and of their metallo-moieties in urine of healthy middle-aged men.
Kanabrocki EL; Sothern RB; Ryan MD; Kahn S; Augustine G; Johnson C; Foley S; Gathing A; Eastman G; Friedman N; Nemchausky BA; Kaplan E
Clin Ter; 2008; 159(5):329-46. PubMed ID: 18998036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
